In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

19. Chen B, Zeng ZC, Wang GM, Zhang L, Lin ZM, Sun LA, et al. Radiotherapy may improve overall survival of patients with t3/t4 transitional cell carcinoma of the renal pelvis or ureter and delay ...

Open radical nephroureterectomy with bladder cuff excision is the standard treatment when pyelocaliceal UTUC invades the ... et al. Centrally infiltrating renal masses on CT: differentiating ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Overall, updated clinical history and additional tumour immune microenvironment composition and cancer cell fraction analyses of the two patients with HNSCC showing divergent response to immunotherapy ...

Background: Urinary tract squamous cell carcinoma (UTSCC) is a rare disease, comprising approximately 3% of histological subtypes from the bladder and urinary tract. Limited data exist to support ...

4506Background: Hypoxia-inducible factor 2-alpha (HIF-2α) is highly dysregulated in clear cell renal cell carcinoma ... Genitourinary Cancer—Kidney and Bladder. May 28, 2025. Share on. Combination ...

Cancer of unknown primary site is an uncommon diagnosis that accounts for 2 to 4% of all cancers. 9 The American Cancer Society estimates that approximately 37,370 new cases of cancer of unknown ...